# OnCo record paper-esmo-ctdna-assay-recommendations-ann-oncol-2022 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-esmo-ctdna-assay-recommendations-ann-oncol-2022/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-esmo-ctdna-assay-recommendations-ann-oncol-2022" ;
  schema:name "ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: a report from the ESMO Precision Medicine Working Group"@en ;
  schema:description "Europe's oncology society advised that blood tests for tumour DNA can guide targeted treatment in advanced cancer, that tissue is still preferred for many patients, and that residual disease tests after surgery were not yet ready for routine use."@en ;
  schema:url <https://onco.cc/key-papers/paper-esmo-ctdna-assay-recommendations-ann-oncol-2022/> ;
  schema:dateModified "2026-10-20"^^xsd:date ;
  schema:citation <https://doi.org/10.1016/j.annonc.2022.05.520>, <https://pubmed.ncbi.nlm.nih.gov/35809752/> ;
  onco:tag "precision", "guideline" ;
  schema:sameAs <https://doi.org/10.1016/j.annonc.2022.05.520> ;
  schema:datePublished "2022"^^xsd:gYear ;
  schema:author "Pascual J, Attard G, Bidard FC, et al." ;
  onco:sections <https://onco.cc/fronts/diagnostics/> ;
  onco:technologies <https://onco.cc/technologies/liquid-biopsy/>, <https://onco.cc/technologies/mrd-testing/>, <https://onco.cc/technologies/mced/> ;
  onco:terms <https://onco.cc/terms/ctdna/>, <https://onco.cc/terms/mrd/> ;
  onco:journals <https://onco.cc/journals/annals-of-oncology/> .